Myocardial Energetic Profiling Using 31P Magnetic Resonance Spectroscopy and Prognostic Assessment Across Heart Failure and Cardiomyopathy Types

What This Trial Is About

Researchers are aiming to create a detailed energetic profile of the heart muscle across a wide range of cardiovascular diseases using a special imaging technique called phosphorus-31 magnetic resonance spectroscopy 31P-MRS. The study will include 1,000 participants, both healthy volunteers and patients with various heart conditions, focusing mainly on heart failure and different types of cardiomyopathies, such as non-ischemic, hypertrophic, ischemic, and other structural heart diseases. The goal is to understand how energy metabolism relates to heart structure and function and to predict clinical outcomes. Participants will undergo combined 31P-MRS and comprehensive cardiac magnetic resonance imaging CMR to measure heart muscle energy levels, specifically the myocardial phosphocreatine to ATP ratio PCrATP. The study groups include healthy individuals and patients with heart failure, non-ischemic cardiomyopathies like hypertrophic and inflammatory types, ischemic cardiomyopathy, other structural heart diseases such as hypertensive and valvular conditions, and inherited cardiomyopathies linked to energy metabolism. This approach allows mapping of disease-specific metabolic signatures and structural heart changes. During the study, participants will have baseline CMR and 31P-MRS scans to assess myocardial energy status. Researchers will follow clinical outcomes, including cardiovascular and heart failure events, for up to three years to evaluate the prognostic value of these energy-related heart changes. The study involves informed consent and requires participants to be able to undergo CMR. The total study duration extends through 2035, with primary outcome assessments occurring by 2030.

31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum